Ultrasensitive and amplification-free detection of SARS-CoV-2 RNA using an electrochemical biosensor powered by CRISPR/Cas13a

Bioelectrochemistry. 2023 Apr:150:108364. doi: 10.1016/j.bioelechem.2023.108364. Epub 2023 Jan 4.

Abstract

This study proposed a CRISPR/Cas13a-powered electrochemical multiplexed biosensor for detecting SARS-CoV-2 RNA strands. Current SARS-CoV-2 diagnostic methods, such as reverse transcription PCR (RT-PCR), are primarily based on nucleic acid amplification (NAA) and reverse transcription (RT) processes, which have been linked to significant issues such as cross-contamination and long turnaround times. Using a CRISPR/Cas13a system integrated onto an electrochemical biosensor, we present a multiplexed and NAA-free strategy for detecting SARS-CoV-2 RNA fragments. SARS-CoV-2 S and Orf1ab genes were detected in both synthetic and clinical samples. The CRISPR/Cas13a-powered biosensor achieved low detection limits of 2.5 and 4.5 ag/µL for the S and Orf1ab genes, respectively, successfully meeting the sensitivity requirement. Furthermore, the biosensor's specificity, simplicity, and universality may position it as a potential rival to RT-PCR.

Keywords: CRISPR; Electrochemical biosensor; Orf1ab gene; S gene; SARS-CoV-2 RNA.

MeSH terms

  • COVID-19* / diagnosis
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Humans
  • Polymerase Chain Reaction
  • RNA, Viral* / genetics
  • SARS-CoV-2 / genetics
  • Sensitivity and Specificity

Substances

  • RNA, Viral